Abstract:Background & Aims Remodeling the tumor microenvironment is a critical strategy for treating advanced hepatocellular carcinoma (HCC). Yet it remains poorly understood how distinct cell populations in the microenvironment mediate tumor resistance to immunotherapy such as anti-PD-1. Methods We analyzed the transcriptomic profiling at a single-cell resolution within tumor tissues from HCC patients scheduled to receive anti-PD-1-based immunotherapy. Our comparative analysis and experimental validation using flow cytometry and histopathological analysis uncovered a discrete subpopulation of cells associated with resistance to anti-PD-1 treatment in HCC patients and a rat model. A TurboID-based proximity labeling approach was deployed to gain mechanistic insights into the reprogramming of the HCC microenvironment. Results Here, we found specifically CD10 + ALPL + NEUs to be associated with resistance to anti-PD-1 treatment. These NEUs exhibited a strong immunosuppressive activity of inducing an apparent "irreversible" exhaustion of T cells in terms of cell number, frequency, and gene profile. Mechanistically, specifically CD10 + ALPL + NEUs were induced by tumor cells, i.e. , tumor-secreted NAMPT reprogrammed CD10 + ALPL + NEUs through NTRK1, maintaining the immature state and inhibiting the maturation and activation of CD10 + ALPL + NEUs. Conclusions Collectively, our results revealed a fundamental mechanism involving CD10 + ALPL + NEUs for tumor immune escape from durable anti-PD-1 treatment and provided further insights into immunotherapy targets or anti-PD-1 synergistic treatment regimens. Impact and implications Herein, we discovered that tumor cells reprogrammed CD10 + ALPL + NEUs to induce the "irreversible" exhaustion of T cells and hence allow the tumors to escape from the intended effects of anti-PD-1 treatment. Our data provided a new theoretical basis for the elucidation of special cell populations and a molecular mechanism underpinning resistance to immunotherapy. Targeting these cells contributed to evaluating indications for immunotherapy and could be looked at as a potentially more effective therapeutic approach.

NLRP3/IL‐1β Induced Myeloid‐derived Suppressor Cells Recruitment and PD‐L1 Upregulation Promotes Oxaliplatin Resistance of Hepatocellular Carcinoma

Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment

METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma

DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC

A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells

Epithelial–mesenchymal Transition Plays a Critical Role in Drug Resistance of Hepatocellular Carcinoma Cells to Oxaliplatin

Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis

Luteolin Sensitizes Two Oxaliplatin-Resistant Colorectal Cancer Cell Lines to Chemotherapeutic Drugs Via Inhibition of the Nrf2 Pathway

The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer

CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma

Oxaliplatin Induces Immunogenic Cell Death in Human and Murine Laryngeal Cancer

LSD1 ‐Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1 ‐Induced p62 Transcription in HCC

HOTAIR/miR-1277-5p/ZEB1 Axis Mediates Hypoxia-Induced Oxaliplatin Resistance Via Regulating Epithelial-Mesenchymal Transition in Colorectal Cancer

Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy

NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma

LINC00460-miR-149-5p/miR-150-5p-Mutant P53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer

Oxaliplatin Induces Apoptosis in Hepatocellular Carcinoma Cells and Inhibits Tumor Growth

Identification of Long Noncoding RNA Expression Profile in Oxaliplatin-Resistant Hepatocellular Carcinoma Cells.

Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy